NCT04404881View on ClinicalTrials.gov

Bevacizumab In Hereditary Hemorrhagic Telangiectasia

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

November 23, 2020

Primary Completion Date

April 1, 2026

Study Completion Date

February 1, 2027

Conditions
Hereditary Hemorrhagic Telangiectasia
Interventions
DRUG

Bevacizumab (Avastin®)

"* Induction Period (first 3 months of bevacizumab treatment):~ \-- Bevacizumab: once every 2 weeks via intravenous infusion for up to 12 weeks.~* Maintenance Period (second 3 months of bevacizumab treatment):~ * Bevacizumab: once every 4 weeks via intravenous infusion for up to 12 weeks."

Trial Locations (1)

02115

Massachusetts General Hospital, Boston

All Listed Sponsors
lead

Hanny Al-Samkari, MD

OTHER